Phase II trial of Temodar (Temozolomide)(TMZ) for SDH-deficient GIST patients has opened for patient recruitment.

The trial is being conducted by Dr. Adam Burgoyne and Dr. Paul Fanta in coordination with Dr. Jason Sicklick at UC San Diego.  Additional trial sites may become available in the future.  Details about the trial can be viewed here:

TMZ is an orally administered DNA altering agent which could also play a role in DNA repair.  Rationale:  Analysis of data involving SDH-deficient pheochromocytoma/paraganglioma from a small clinical trial in France found a 50% response rate.

TMZ  would be taken for 21 days, followed by a 7 days without treatment for a 28 day cycle, with a treatment duration of 6 months.  Radiological assessment would take place every 8 weeks.

Questions about the trial can be directed to:

Julie Lewis, CRC, LVN

phone: 858-822-4907 Pager 619-290-1378